This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

- 1.(currently amended) A pharmaceutical liposomal formulation for photodynamic therapy, which can be safely freeze-dried and reconstituted, comprising a lipid bilayer which consists substantially of synthetic phospholipids, a monosaccharide, and a therapeutically effective amount of a non-polar di- or tetrahydro\_porphyrin derivative. selected from the group consisting of chlorin, bacteriochlorin, porphyrinogen and iso bacteriochlorin.
- 2. (currently amended) The liposomal formulation according to claim 1, wherein said <u>synthetic</u> phospholipids are selected from the group consisting of dipalmitoyl phosphatidyl choline, dipalmitoyl phosphatidyl glycerol, <del>poly (ethylene glycol)-linked phospholipids</del> and combinations of these <del>three</del> materials.
- 3.(cancelled)
- 4.(cancelled)
- 5.(cancelled)
- 6.(currently amended) The liposomal formulation according to claim [5] 1 wherein said monosaccharide is selected from the group consisting of glucose and fructose.
- 7.(cancelled)
- 8.(currently amended) The liposomal formulation according to claim [5] 1 wherein the concentration ratio of monosaccharide to phospholipid is between 1:2 and 1:12.
- 9.(cancelled)
- 10.(currently amended) The liposomal formulation according to claim [5] 1, reconstituted with an aqueous fluid for pharmaceutical administration.
- 11.(original) The liposomal formulation according to claim 1 wherein the therapeutically effective concentration of the photosensitizer is from 0.0001 to 0.15 percent w/v.

Appl. No 10/648,168 Reply to the Office Action dated 6/9/2005 Page 3 of 7

- 12.(cancelled)
- 13.(original) The liposomal formulation according to claim 1 further comprising a component selected from the group consisting of butylated hydroxytoluene, ascorbic palmitate, and combinations of these two.
- 14.(cancelled)
- 15.(cancelled)
- 16.(cancelled)